CERA: New scourge of the peloton

Doping

With doping back in the headlines after the news of Davide Rebellin and Stefan Schumacher's positives at the 2008 Olympic Games, we take a look at the substance they tested positive for - CERA.

CERA or Continuous Erythropoiesis Receptor Activator is a new form of EPO, created by the Swiss company Roche, that has been created to help dialysis patients or people with kidney problems.

The drug stimulates the kidneys to produce EPO which in turn stimulates the bone marrow to increase the creation of red blood cells. More red blood cells allow the body to carry more oxygen and so increases an athlete's performance.

CERA offers 'benefits' over older forms of EPO because it is has a slower release rate or creation of red blood cells in the body. For patients that means fewer injections, perhaps even just once a month, and lower health care costs for hospitals.

Click on the names below to read a full report on each rider's case:

Thank you for reading 20 articles this month* Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read 5 free articles per month without a subscription

Join now for unlimited access

Try first month for just £1 / $1 / €1

Founded in 1891, Cycling Weekly and its team of expert journalists brings cyclists in-depth reviews, extensive coverage of both professional and domestic racing, as well as fitness advice and 'brew a cuppa and put your feet up' features. Cycling Weekly serves its audience across a range of platforms, from good old-fashioned print to online journalism, and video.